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PChord-TAV strain distribution was up to 42% lower than for fabricated chordless valves.
Chord-TAVs exhibited satisfactory hydrodynamics for size 23 valves. Initial AWT
testing data indicated that strain reduction continues following cyclic loading (Fig.1). O
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SConclusions: Chord-TAVs with chordal reinforcement provided structural support
that greatly reduced leaﬂet stress and strain. Such reduction will improve valve
performance and overall valve durability.
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Background: A strong component of predicted mortality in scoring systems is
advanced age, however, outcomes data in nonagenarians (age >90 years) is lacking.
We evaluated surgical outcomes after aortic valve replacement (AVR) in nonage-
narians at our institution over an 11-year period.
Methods: Demographics, procedural details, and in-hospital outcomes were retro-
spectively analyzed on 119 patients with severe aortic stenosis (AS) who underwent
AVR or AVR+concomitant surgery between 2001 and 2012. Mean duration of
follow-up was 915832 days.
Results: The average age was 91.71.9 years (range 90-97) and mean STS score was
8.95.7. Over 98% of patients met echocardiographic criteria for severe AS (mean
gradient 45.016.1 mmHg, aortic valve area 0.660.2 cm2), had an ejection fraction
of 49.811.8%, and 47% underwent an isolated AVR. Though average length of stay
was longer than expected, rates of prolonged ventilation (16.8%), new atrial ﬁbrilla-
tion (43.7%), stroke (0.8%), and renal failure (5.9%) were acceptable. Three patients
(2.5%) required reoperation for bleeding. Overall 30 day or in-hospital mortality was
7.6%, and multivariate predictors of mortality at 1 years included prior myocardial
infarction (HR 2.79, 95% CI: 1.21-6.45, p¼0.016), obstructive lung disease (HR 3.90,
95% CI: 1.66-9.15, p¼0.025), and diabetes (HR 2.77, 95% CI: 1.08-7.07, p¼0.033).
Observed mortality at 30 days was lower than expected (observed/expected¼0.85).Table 1. Demographics and Procedural Outcomes
Concomitant surgery status, n (%)
Isolated AVR 56 (47.1%)
AVR + CABG 47 (39.5%)
AVR + MVR 10 (8.4%)
AVR + Other 6 (5.0%)
Duration of hospital stay in days
Overall 16.511.7
Isolated AVR 13.99.1
AVR + any surgery 18.713.2
Re-operation for bleeding, n (%) 3 (2.5%)
30-day or in-hospital mortality, n (%) 9 (7.6%)
Cumulative mortality at 1 year
Isolated AVR 16.1%
AVR+any surgery 25.4%
AVR- aortic valve replacement, CABG- coronary artery bypass grafting, MVR-mitral valve
replacement.Conclusions: Excellent procedural and long-term outcomes can be achieved in
nonagenarians, and age alone should not be a contraindication for valve replacementJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrin select populations. This sample cohort validates the feasibility of a primary oper-
ative strategy in elderly patients with AS and acceptable risk proﬁles.
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Background: The incidence of transcatheter heart valve (THV) device malposition is
higher during aortic valve-in-valve implantation (VinV). We aimed to evaluate for
correlates for this complication.
Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry
were investigated (459 procedures, 246 Edwards SAPIEN and 213 CoreValve).
Results: THV device malposition occurred in 50 cases (10.9%) resulting in attempted
device retreival (10.3% of CoreValve implantations) and second THV device
implantation (7.5% CoreValve vs. 4.1% Edwards SAPIEN, p¼0.052). Device
malposition was more common during CoreValve VinV procedures(16.4% vs. 6.1%,
Edwards SAPIEN, p¼0.0004). In Edwards SAPIEN VinV procedures there was no
difference in malposition rate between transfemoral and transapical procedures (4.1%
vs. 7%, p¼0.39). Device malposition was more common in procedures performed
early in the learning-curve (14.4% vs. 9% after the seventh case per center, p¼0.046),
with regurgitant bioprostheses (13.3% vs. 7.2% in bioprostheses with isolated
stenosis, p¼0.04) and with stentless and Mosaic stented valves (16.1%,14.0% vs.
9.0% in non-Mosaic stented valves, p¼0.04).
Conclusions: Device malposition is common during aortic VinV procedures and may
result implantation of a second THV device. Malposition was more common when
performed early in the learning curve, with CoreValve VinV procedures and with
regurgitant, stentless and Mosaic bioprostheses.
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Background: Low-Flow Low-Gradient (LF-LG) or "Paradoxical Aortic Stenosis" is
a rarely encountered clinical entity with limited data on clinical outcomes after
surgical (SAVR) or trans-catheter aortic valve (TAVI) replacement. We conducted
a meta-analysis of all the studies comparing all-cause mortality after aortic valve
replacement in LF-LG AS in comparison to medical therapy alone.
Methods: A thorough PubMed (time-unlimited till 06/01/2013) search revealed 5
studies comparing TAVI/SAVR outcomes in LF-LG aortic stenosis (mean gradient
<40mmHg; stroke volume index <35ml/m2). Primary clinical endpoint was all-cause
mortality at 2 year follow-up. Odds ratio (OR) and conﬁdence interval (CI) were
estimated using the random effects model.
Results: A total of 607 patients (SAVR/TAVI 263; medical therapy 344) were
included in the analysis. Baseline characteristics of these patients in valve
replacement and medical therapy arms were comparable. At 2-year follow-up,
SAVR/TAVI was associated with lower all-cause mortality (24.3% vs. 55.8%; OR
0.23; 95% CI 0.15 – 0.36). This corresponds to an absolute risk reduction of 31.5%
and a Number Needed to Treat 3.55 to save one life.acts/POSTER/Aortic Valve Disease and Treatment B231
Pacing insertion and utilisation data for 4 CoreValve TAVI centres
Centre A B C D
Total number of
TAVI cases
229 132 198 262
Overall pacing
rate % (p<0.05)
22.7 9.1* 24.7 16.8
Duration after
TAVI of PPM
(days)(p<0.05)
3.8 6.5* 3.4 4.6
Depth of implant
(mm)
6.7 8.1 7.0 7.2
Atrial pacing 6
weeks %
(p<0.05)
22.6 52* 43.5 16.5
Atrial pacing 6
months %
20.9 25.6 44.8 23
Atrial at latest
follow-up %
23.2 39 23 23.2
Ventricular pacing
6 weeks %
(p<0.05)
64.9 84.5* 79.7 59.2
Ventricular pacing
6 months %
43.4 69.6 81.4 59.1
Ventricular pacing
latest follow-up %
(p<0.05)
47.1 84.7* 78 62.2
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SConclusions: Patients with LF-LG aortic stenosis experience very high 2-year
mortality in the absence of valve replacement. Valve replacement with surgical or
trans-catheter approach results in improved 2-year survival and saves 1 life for every
3.6 patients treated with SAVR/TAVI. Data on outcomes of TAVI in these complex
patients continues to evolve and mandates heart team approach in clinical decision
making.
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Background: Bleeding after TAVI still remains a frequent and potentially serious
complication. A common cause of bleeding in this population might be represented by
excessive intraprocedural anticoagulation with heparin. Adjusted heparin dose
administration using baseline ACT guidance may reduce the risk of overdosing in this
frail population. The aim of our study is to evaluate the impact of the Activated
Clotting Time (ACT)-guided heparin administration on bleeding occurrence during
trans-femoral (TF) Transcatheter Aortic Valve Implantation (TAVI).
Methods: Among 362 patients undergoing TF-TAVI, heparin was administered
according to two strategies: baseline ACT (ACT-guided, n¼174) or patient's body
weight (non ACT-guided n¼188 patients). The primary study objective was 30-day
major bleeding occurrence as deﬁned by the Valve Academic Research Consortium
(VARC) criteria. Secondary objectives were any life-threatening and minor bleeding,
vascular complications, acute kidney failure, myocardial infarction, stroke, all-cause
and cardiovascular mortality at 30 days according to VARC.
Results: Bleeding occurred in 167 (46.1%) patients; of these 76 (21.0%) had major
bleeding. Of note, the ACT-guided group had a signiﬁcant lower occurrence of
major (7.5% vs. 33.5%, p <0.001), life-threatening (12.1% vs. 20.2%, p¼0.04) and
any bleeding (25.9% vs.64.9%, p <0.001). Conversely, no differences were noted in
the other secondary study objectives. Importantly, irrespective of the time the
procedure was performed (experience phase) and of the operator preference in heparin
administration, the ACT-guided strategy was associated with a signiﬁcant lower
occurrence of major bleeding at 30 days. Moreover, after multivariate adjustment for
potential confounders ACT-guided propensity, the absence of ACT guidance was
an independent predictor of major bleeding at 30 days [OR 6.4, 95%CI (2.3-17.9),
p< 0.001].
Conclusions: In our experience, ACT guidance in TF-TAVI was correlated with
a signiﬁcant lower occurrence of major, life-threatening and any bleeding. This
strategy might be an useful tool in reducing bleeding in this high-risk population.
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Background: Permanent pacemaker (PPM) requirement is a recognised complication
of Transcatheter Aortic Valve implantation (TAVI) (published rate of 16-40%) and
surgical aortic valve replacement(AVR)(8% of cases). PPM requirement post
CoreValve TAVI is inﬂuenced by 3 main factors: 1) electrocardiogram predictors, 2)
depth of CoreValve below annulus,3) timing of pacing decision. Early pacing
may allow earlier discharge but this may contribute to higher pacing rates.PPM uti-
lisation and how this relates to pacing rates in TAVI patients has not previously been
studied.
Methods: Data from a total of 821 consecutive patients treated between 2008 and
July 2012 with CoreValve in the four UK TAVI centres (A, B, C and D) was
examined. A retrospective analysis of all patients who received a pacemaker was
performed.
Results: Pre-TAVI electrocardiogram revealed a similar distribution of conduction
abnormalities in patients who required a PPM. Centre B had a signiﬁcantly (p<0.05)B232 JACC Vol 62/18/Suppl B j October 27–Novemberlower overall pacemaker rate (see table). All centres had a procedural management
strategy of high implantation of CoreValve. However, in patients receiving PPM, this
was not achieved and average depth of valve base from aortic annulus was measured
(Centre A 6.73mm, B 8.12mm, C 7.02mm and D 7.18mm, p¼NS). The decision to
pace was made signiﬁcantly later in centre B (mean of 6.5 days post TAVI compared
to 3.8 days in centre A, 3.4 days in centre C and 4.6 days in D, p<0.01), which may
then be reﬂected in the subsequent patient pacing requirement(see table).
Centre B recorded a signiﬁcantly lower overall pacing rate. This was associated
with a longer time taken for decision to pace but signiﬁcantly higher pacemaker
utilisation and less pacemaker redundancy.Conclusions: Pacing rates in each of the 4 centres was lower than previously reported
(9-24%vs 16-40%). In one centre, the pacing rate was similar to traditional surgery
(9%). Early PPM insertion (<3days) led to a higher PPM rate but low utilisation.
Whereas, a delay in decision to insert PPM appears to be associated with a lower
overall insertion rates and reduced redundancy in the inserted pacemakers.
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Background: Transcatheter aortic valve implantation (TAVI) is an increasingly
common procedure in elderly and multimorbid patients with aortic stenosis. A pre-
procedural risk evaluation scheme beyond current surgical risk scores has not been
widely implemented.
Methods: We developed a risk algorithm for 1-year mortality in two cohorts con-
sisting of 845 patients undergoing routine transapical or transfemoral TAVI proce-
dures by commercially available devices, mean age 80.96.5, 51% women. Clinically
available variables and surgical risk scores were determined at baseline. Multivariable
Cox regression related clinical data to mortality (n¼207 deaths).
Results: Age, sex, body mass index, estimated glomerular ﬁltration rate, hemoglobin,
pulmonary hypertension, and mean transvalvular gradient and left ventricular ejection
fraction at baseline were most strongly associated with mortality (C-statistic 0.66, 95%
conﬁdence interval [CI] 0.61 to 0.70, calibration Chi2 statistic¼ 6.51; p¼0.69). B-type
natriuretic peptide and troponin I were signiﬁcantly related to outcome after multi-
variable-adjustment, but did not improve the C-statistic. Frailty increased the C-
statistic to 0.71 (95% CI 0.65 to 0.76).
Conclusions: We present a speciﬁc risk evaluation tool derived and validated in
routine TAVI cohorts that predicts 1-year mortality better than the conventional
scoring systems. Biomarkers only marginally improved risk prediction. Our risk
algorithm may help to guide decision-making when TAVI is planned.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
